These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 10898681)

  • 1. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents.
    Robinson BS; Riccardi KA; Gong YF; Guo Q; Stock DA; Blair WS; Terry BJ; Deminie CA; Djang F; Colonno RJ; Lin PF
    Antimicrob Agents Chemother; 2000 Aug; 44(8):2093-9. PubMed ID: 10898681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632.
    Gong YF; Robinson BS; Rose RE; Deminie C; Spicer TP; Stock D; Colonno RJ; Lin PF
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2319-26. PubMed ID: 10952574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro.
    Patick AK; Boritzki TJ; Bloom LA
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2159-64. PubMed ID: 9333041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.
    Hazen R; Harvey R; Ferris R; Craig C; Yates P; Griffin P; Miller J; Kaldor I; Ray J; Samano V; Furfine E; Spaltenstein A; Hale M; Tung R; St Clair M; Hanlon M; Boone L
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3147-54. PubMed ID: 17620375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atazanavir/ritonavir: a review of its use in HIV therapy.
    von Hentig N
    Drugs Today (Barc); 2008 Feb; 44(2):103-32. PubMed ID: 18389089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication.
    Deminie CA; Bechtold CM; Stock D; Alam M; Djang F; Balch AH; Chou TC; Prichard M; Colonno RJ; Lin PF
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1346-51. PubMed ID: 8725999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors.
    Colonno RJ; Thiry A; Limoli K; Parkin N
    Antimicrob Agents Chemother; 2003 Apr; 47(4):1324-33. PubMed ID: 12654666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of human immunodeficiency virus type 1 Pr55(Gag) and Pr160(Gag-pol) processing intermediates that accumulate in primary and transformed cells treated with peptidic and nonpeptidic protease inhibitors.
    Speck RR; Flexner C; Tian CJ; Yu XF
    Antimicrob Agents Chemother; 2000 May; 44(5):1397-403. PubMed ID: 10770790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro.
    Merrill DP; Moonis M; Chou TC; Hirsch MS
    J Infect Dis; 1996 Feb; 173(2):355-64. PubMed ID: 8568296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease.
    Lamarre D; Croteau G; Wardrop E; Bourgon L; Thibeault D; Clouette C; Vaillancourt M; Cohen E; Pargellis C; Yoakim C; Anderson PC
    Antimicrob Agents Chemother; 1997 May; 41(5):965-71. PubMed ID: 9145853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
    Le Tiec C; Barrail A; Goujard C; Taburet AM
    Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atazanavir: A novel once-daily protease inhibitor.
    Piliero PJ
    Drugs Today (Barc); 2004 Nov; 40(11):901-12. PubMed ID: 15645003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of human immunodeficiency virus type 1 replication by combination of transcription inhibitor K-12 and other antiretroviral agents in acutely and chronically infected cells.
    Okamoto M; Okamoto T; Baba M
    Antimicrob Agents Chemother; 1999 Mar; 43(3):492-7. PubMed ID: 10049256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro antiviral interaction of lopinavir with other protease inhibitors.
    Molla A; Mo H; Vasavanonda S; Han L; Lin CT; Hsu A; Kempf DJ
    Antimicrob Agents Chemother; 2002 Jul; 46(7):2249-53. PubMed ID: 12069982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro.
    Vermeire K; Princen K; Hatse S; De Clercq E; Dey K; Bell TW; Schols D
    AIDS; 2004 Nov; 18(16):2115-25. PubMed ID: 15577644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral properties of aminodiol inhibitors against human immunodeficiency virus and protease.
    Bechtold CM; Patick AK; Alam M; Greytok J; Tino JA; Chen P; Gordon E; Ahmad S; Barrish JC; Zahler R
    Antimicrob Agents Chemother; 1995 Feb; 39(2):374-9. PubMed ID: 7726501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro.
    Essey RJ; McDougall BR; Robinson WE
    Antiviral Res; 2001 Sep; 51(3):189-202. PubMed ID: 11448730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir.
    Dam E; Lebel-Binay S; Rochas S; Thibaut L; Faudon JL; Thomas CM; Essioux L; Hill A; Schutz M; Clavel F
    Antivir Ther; 2007; 12(3):371-80. PubMed ID: 17591027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors.
    Yanchunas J; Langley DR; Tao L; Rose RE; Friborg J; Colonno RJ; Doyle ML
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3825-32. PubMed ID: 16127059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.